Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Taysha Gene Therapies Inc (NQ: TSHA )

2.700 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 23, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 2.700
Bid (Size) 2.690 (3)
Ask (Size) 4.880 (1)
Prev. Close 2.700
Today's Range 2.700 - 2.700
52wk Range 2.620 - 26.99
Shares Outstanding 40,546,392
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Expert Ratings for Taysha Gene Therapies
Within the last quarter, Taysha Gene Therapies (NASDAQ:TSHA) has observed the following analyst ratings: 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
On Monday, 198 companies reached new 52-week lows. 
Via Benzinga

Performance

YTD
-77.23%
-77.23%
1 Month
-43.28%
-43.28%
3 Month
-55.88%
-55.88%
6 Month
-77.08%
-77.08%
1 Year
-88.00%
-88.00%

More News

Read More
Taysha Gene Therapies: Q1 Earnings Insights
Via Benzinga
Earnings Scheduled For May 16, 2022
Via Benzinga
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Taysha Gene Therapies Lays Off 35% Of staff, Narrows R&D Focus
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
What 6 Analyst Ratings Have To Say About Taysha Gene Therapies
Via Benzinga
10 Biggest Price Target Changes For Friday
Via Benzinga
Recap: Taysha Gene Therapies Q4 Earnings
Via Benzinga
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
Via Benzinga
Taysha Gene Therapies Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies's Earnings Outlook
Via Benzinga
Earnings Scheduled For March 31, 2022
Via Benzinga
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict
Via Benzinga
Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome
From Taysha Gene Therapies, Inc.
Via Business Wire
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Via Benzinga
Taysha Gene Therapies Earnings Conference Call Is Coming Up, Here's What You Need To Know
Via Benzinga
Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 31
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies to Participate in Upcoming April Investor Healthcare Conferences
From Taysha Gene Therapies, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2022
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.